Title |
Sensitization of U937 leukemia cells to doxorubicin by the MG132 proteasome inhibitor induces an increase in apoptosis by suppressing NF-kappa B and mitochondrial membrane potential loss
|
---|---|
Published in |
Cancer Cell International, February 2014
|
DOI | 10.1186/1475-2867-14-13 |
Pubmed ID | |
Authors |
Pablo César Ortiz-Lazareno, Alejandro Bravo-Cuellar, José Manuel Lerma-Díaz, Luis Felipe Jave-Suárez, Adriana Aguilar-Lemarroy, Jorge Ramiro Domínguez-Rodríguez, Oscar González-Ramella, Ruth De Célis, Paulina Gómez-Lomelí, Georgina Hernández-Flores |
Abstract |
The resistance of cancerous cells to chemotherapy remains the main limitation for cancer treatment at present. Doxorubicin (DOX) is a potent antitumor drug that activates the ubiquitin-proteasome system, but unfortunately it also activates the Nuclear factor kappa B (NF-кB) pathway leading to the promotion of tumor cell survival. MG132 is a drug that inhibits I kappa B degradation by the proteasome-avoiding activation of NF-кB. In this work, we studied the sensitizing effect of the MG132 proteasome inhibitor on the antitumor activity of DOX. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 2% |
Unknown | 45 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 11 | 24% |
Researcher | 8 | 17% |
Student > Ph. D. Student | 8 | 17% |
Student > Bachelor | 6 | 13% |
Professor | 2 | 4% |
Other | 5 | 11% |
Unknown | 6 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 16 | 35% |
Biochemistry, Genetics and Molecular Biology | 10 | 22% |
Medicine and Dentistry | 6 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
Physics and Astronomy | 1 | 2% |
Other | 3 | 7% |
Unknown | 7 | 15% |